Arrêt du traitement par inhibiteurs de tyrosine-kinase

Réa, D.; Mahon, F.
October 2012
Oncologie;Oct2012, Vol. 14 Issue 10/11, p606
Academic Journal
After more than a decade of treatment of chronic myeloid leukemia (CML) patients with the BCR-ABL tyrosine-kinase inhibitor imatinib, and despite the impressive results obtained with the use of this targeted therapy, the major question of how to cure CML remains unresolved. The next step for the future will be to address this key issue. CML is a model disease with a defined oncogenic driver, the BCR-ABL oncoprotein. The fact that the majority of CML patients who respond very well to BCR-ABL targeted therapy show evidence of molecular recurrence upon treatment discontinuation focuses the attention on the need for further research on the persistence of leukemic stem cells. The challenge now is to understand why, after stopping the treatment, leukemia recurs in some patients but not in others. Wining this battle is a challenge and will certainly benefit the treatment and management of other leukemias and solid tumors and will validate this new topic.


Related Articles

  • Inhibiteur de tyrosine-kinase de 1 génération: place des associations. Guilhot, F. // Oncologie;Oct2012, Vol. 14 Issue 10/11, p583 

    Chronic myeloid leukemia (CML) is a malignant disorder in which the immune system has been described as important for the graft versus leukemia effect after stem cell transplantation. With imatinib at a dose of 400 mg, the current treatment of chronic phase CML does not eradicate the leukemic...

  • Spotlight on nilotinib in the treatment of chronic myelogenous leukemia. Harnicar, Stephen; Mathew, Sherry // Blood & Lymphatic Cancer: Targets & Therapy;Aug2014, Vol. 4, p61 

    Nowhere has targeted therapy been more successful in the hematologic malignancy arena than chronic myelogenous leukemia (CML). By targeting the BCR-ABL fusion oncogene, the introduction of tyrosine-kinase inhibitors (TKIs) has dramatically improved the outcomes of this disease. Nilotinib is a...

  • Cancer: Repositioned to kill stem cells. Holyoake, Tessa; Vetrie, David // Nature;9/17/2015, Vol. 525 Issue 7569, p328 

    The article discusses the treatment of chronic myeloid leukaemia (CML) through targeting drug-resistant leukaemic stem cells (LSCs), referencing a study coauthored by the scientist S. Prost which appears within the issue. An overview of the development of tyrosine kinase inhibitors (TKIs) is...

  • Inhibiteurs de tyrosine-kinase de 2 génération et associations: perspectives. Coiteux, V. // Oncologie;Oct2012, Vol. 14 Issue 10/11, p601 

    Second-generation tyrosine-kinase inhibitors enable an earlier and higher quality molecular response to be achieved than with imatinib in patients suffering from CML in chronic phase at diagnosis. This implies that in the future a larger number of patients will be candidates for the...

  • For 'Bosutinib,' it's Caveat Emptor.  // BioWorld Today;5/21/2012, Special section p2 

    The article reports on the discovery by scientists from Stanford University that there are two distinct chemical compounds being sold as bosutinib, a possible third-line agent for the treatment of chronic myelogenous leukemia, by commercial vendors.

  • FDA actions. Elliott, William T. // Infectious Disease Alert;Dec2012 Pharmacology Watch, p2 

    The article offers information on a drug approved by the U.S. Food and Drug Administratioin (FDA) for treating chronic myelogenous leukemia (CML) with the tyrosine kinase inhibitors (TKIs) therapy such as perampanel for patients with partial onset seizures.

  • Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL. Breccia, Massimo; Alimena, Giuliana // Current Drug Targets;Jun2009, Vol. 10 Issue 6, p530 

    Imatinib mesylate is currently the standard therapy for chronic myeloid leukemia (CML) patients. Despite the remarkable results achieved with imatinib, the emergence of resistance to this drug has become a significant problem. Several strategies have been developed to overcome imatinib...

  • European Society of Hematology.  // BioWorld Today;6/9/2009, Vol. 20 Issue 109, p6 

    The article discusses the data reported by ChemGenex Pharmaceuticals Ltd. from 65 patients in its Phase II/III trial of omacetaxine in chronic myeloid leukemia that are resistant to multiple tyrosine kinase inhibitor therapy. An 80% complete hematologic response rate was observed in chronic...

  • Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy. Pytel, Dariusz; Sliwinski, Tomasz; Poplawski, Tomasz; Ferriola, Deborah; Majsterek, Ireneusz // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 1, p66 

    Tyrosine kinases (TKs) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth. Constitutive activated TKs stimulate multiple signaling pathways responsible for DNA repair, apoptosis, and cell proliferation. During the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics